Vicki Moore, PhD

Contributing Writer https://www.renalandurologynews.com

Vicki Moore, PhD, is a freelance medical writer for Hematology Advisor. Vicki received her PhD in biology from Arizona State University, where her research emphasized molecular biology, biochemistry, and metabolic engineering. She also has experience with predictive analytics and is intrigued by its applications to medicine. Vicki has been a medical writer, focusing on areas of hematology and oncology, among other specialties, since late 2017. You can find her on Linkedin at linkedin.com/in/vicki-moore-93950913

All articles by Vicki Moore, PhD

Urology

Apixaban Compared With Dalteparin in Cancer-Related Venous Thromboembolism

Vicki Moore, PhD

January 10, 2023

Researchers sought to compare oral apixaban and subcutaneous dalteparin for treating patients with cancer-related venous thromboembolism.

Doctor escorting senior man down the hall

Prostate Cancer

Body Composition and Pelvic Fat Distribution Linked to Prostate Cancer Outcomes

Vicki Moore, PhD

November 1, 2022

Researchers sought to determine the relationship between body composition and pelvic fat distribution and prostate cancer aggressiveness and recurrence.

In Patients With Renal Cell Carcinoma Receiving Everolimus, Acute Kidney Injury is Common

News

Acute Kidney Injury After CAR-T Therapy for Non-Hodgkin Lymphoma

Vicki Moore, PhD

August 26, 2022

Researchers sought to determine the incidence and possible risk factors of acute kidney injury in patients undergoing a chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.

Association Between Cabozantinib and Skin Reactions in Patients with Urothelial Carcinoma

Bladder Cancer

Cutaneous Adverse Effects Common With Enfortumab Vedotin for Urothelial Cancer

Vicki Moore, PhD

April 4, 2022

Researchers described dermatologic events associated with the use of enfortumab vedotin in treatment of locally advanced/metastatic urothelial cancer.

Kidney Cancer

Preoperative Blood Glucose Level Linked to Length of Stay After Nephrectomy for Renal Cell Carcinoma

Vicki Moore, PhD

September 22, 2021

Researchers found preoperative blood glucose levels were associated with hospital length of stay for patients undergoing laparoscopic nephrectomy for RCC.

Prostate Cancer

Baseline Fatigue as a Predictor of Mortality Outcomes in Prostate and Lung Cancer

Vicki Moore, PhD

August 25, 2021

Clinically significant fatigue at baseline was identified as a predictive factor for mortality in studies of 2 forms of cancer treated with chemotherapy.

Anemia

Anemia May Increase Risks of Ischemic Stroke and Poststroke Mortality

Vicki Moore, PhD

August 6, 2021

Researchers sought to determine whether patients with anemia had an increased risk of ischemic stroke and poststroke mortality.

There is great interest in evaluating the link between hypercalcemia and prognosis in ccRCC by researching the genes that influence calcium levels.

Kidney Cancer

Classifier Predicts Efficacy of Immune Checkpoint Inhibitor Therapy in Renal Cell Carcinoma

Vicki Moore, PhD

July 26, 2021

Researchers applied a 27-gene classifier proven effective with breast, lung, and bladder cancers to predict efficacy of ICI therapy in patients with RCC.

Genitourinary Cancers Symposium

Bladder Pressure May Influence Intravesical Drug Delivery

Vicki Moore, PhD

March 4, 2021

Using porcine bladders, researchers investigated whether bladder pressure affects the extent to which gemcitabine penetrates the bladder wall with this treatment modality.

Close to 60% of all patients with VHL will develop RCC or renal cysts.

Kidney Cancer

Bone-Targeted Therapies and Incidence of Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma

Vicki Moore, PhD

February 11, 2021

A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC and bone-targeted therapies for bone metastases.

Next post in Kidney Cancer